TVTX vs. LRMR, ATXS, VERV, KALV, OCS, APLT, YMAB, AVTE, ABUS, and ANL
Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Larimar Therapeutics (LRMR), Astria Therapeutics (ATXS), Verve Therapeutics (VERV), KalVista Pharmaceuticals (KALV), Oculis (OCS), Applied Therapeutics (APLT), Y-mAbs Therapeutics (YMAB), Aerovate Therapeutics (AVTE), Arbutus Biopharma (ABUS), and Adlai Nortye (ANL). These companies are all part of the "pharmaceutical preparations" industry.
Larimar Therapeutics (NASDAQ:LRMR) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking.
Travere Therapeutics received 25 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. However, 60.87% of users gave Larimar Therapeutics an outperform vote while only 48.62% of users gave Travere Therapeutics an outperform vote.
Larimar Therapeutics currently has a consensus price target of $20.00, suggesting a potential upside of 170.64%. Travere Therapeutics has a consensus price target of $16.69, suggesting a potential upside of 169.23%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Larimar Therapeutics is more favorable than Travere Therapeutics.
In the previous week, Larimar Therapeutics had 1 more articles in the media than Travere Therapeutics. MarketBeat recorded 6 mentions for Larimar Therapeutics and 5 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 0.84 beat Larimar Therapeutics' score of 0.11 indicating that Larimar Therapeutics is being referred to more favorably in the media.
Larimar Therapeutics has a net margin of 0.00% compared to Larimar Therapeutics' net margin of -87.94%. Travere Therapeutics' return on equity of -35.69% beat Larimar Therapeutics' return on equity.
Larimar Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.
91.9% of Larimar Therapeutics shares are held by institutional investors. 4.3% of Larimar Therapeutics shares are held by insiders. Comparatively, 4.1% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Larimar Therapeutics has higher earnings, but lower revenue than Travere Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Larimar Therapeutics beats Travere Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Travere Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Travere Therapeutics Competitors List
Related Companies and Tools
